Email Newsletters

Life Sciences

Southborough Firm Lands $6M In Financing

Medical testing specialist SynapDx Corp. of Southborough has secured $6 million in financing from two investors to...

Marlborough Gets Biotech Industry Nod

The Massachusetts Biotechnology Council has upgraded its “biotech readiness” rating for the city of Marlborough, city officials announced.

Worcester Site Part Of Abbott Split

Abbott Laboratories will spin off its research-based pharmaceuticals division into a separate business, a move that includes...

UMMS Receives $1.6M National Grid Incentive

The energy efficient features of new Albert Sherman Center (ASC) have earned its owner, the University of...
ADVERTISEMENT

Agilux Laboratories Awarded Accreditation

Worcester-based pharmaceutical and biotech research firm Agilux Laboratories announced that it has received accreditation from the Association...

ACT Makes Progress In Clinical Trials

Marlborough-based Advanced Cell Technology (ACT) has finished treating three more patients in its two U.S. clinical trials...

Boston Scientific: Moving Right Along

When Boston Scientific Corp. decided to move its headquarters from Natick to Marlborough, the issue was one...

HeartWare Device Wins FDA Approval

HeartWare International of Framingham has received federal government approval for a product that aids heart transplant patients...
ADVERTISEMENT

BSX Reportedly Loses Bid For Gene Therapy Rights

A California company announced it has won patent rights to key methods for the application of cardiovascular...

Framingham Firm Passes Another FDA Step

Dune Medical Devices of Framingham has passed another federal approval phase for a breast-cancer surgical tool, MarginProbe,...
ADVERTISEMENT

Latest Stories

More Business News
ADVERTISEMENT

Thought Leadership

More Thought Leadership

Career Opportunities

More Jobs | Submit a Job
More Events | Submit an Event

Get our email newsletter

Stay up-to-date on the companies, people and issues that impact businesses in Central Massachusetts.

Close the CTA